Rhythm Pharmaceuticals has delivered very strong share price gains over the past five years, yet the current valuation checks point to a stock that now screens as expensive rather than a clear bargain.

• The share price has risen a little more than 6x over the past five years, which puts extra focus on whether that past return is already reflected in today's valuation.
• Expectations for continued revenue growth may support the current price, while any setback in execution or higher than expected cash needs could put pressure on how much investors are willing to pay.
• The company has a mixed valuation profile, with the broader checks indicating it is fairly priced in some respects and stretched in others, scoring 3 out of 6 on our valuation framework.

The key question now is whether Rhythm Pharmaceuticals' recent share price level still leaves enough valuation support for new investors coming in after such a strong multi year run.

Has Rhythm Pharmaceuticals Run Too Far on Sales?

The P/S multiple suits Rhythm Pharmaceuticals because the company is still loss making and investors are mostly focused on revenue traction. Rhythm Pharmaceuticals currently trades on a P/S of about 31.3x. That is roughly three times the broader biotech industry average of 10.5x and also well above the peer group average of about 9.6x.

On Simply Wall St's fair ratio framework, which looks at factors such as growth expectations, margins, size and risk, Rhythm Pharmaceuticals is assigned a fair P/S of about 19.8x. The current 31.3x level sits materially above that benchmark, which indicates that investors are already paying a premium for the stock compared with what the model suggests is reasonable.

Using the preferred P/S multiple, Rhythm Pharmaceuticals appears overvalued, with a valuation that sits well above both industry norms and the modelled fair ratio.

The Rhythm Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Rhythm Pharmaceuticals build on the valuation puzzle above and set out clear scenarios that describe what kind of future growth, margins and earnings paths would need to occur for the stock to be worth meaningfully more or less than today’s price. Each narrative links its figures to a specific view on how Rhythm Pharmaceuticals' growth, margins and risks might evolve, which you can revisit on the Community page as new information becomes available.

You can share your own Narrative on Rhythm Pharmaceuticals and be one of the first voices in the Simply Wall St community to set out a clear, number driven view on where its growth, margins and execution go from here. Build a case you can track over time as Rhythm Pharmaceuticals' story develops and new data arrives.

Do you think there's more to the story for Rhythm Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Rhythm Pharmaceuticals now screens as overvalued on the preferred P/S measure, with the current multiple sitting well above both sector norms and the modelled fair ratio. The broader checks are mixed rather than clearly supportive, so the stock no longer looks like an obvious value opportunity after such a strong multi year move. The key question for investors is whether Rhythm Pharmaceuticals can deliver enough durable revenue growth and margin progress to keep justifying this premium, or whether expectations eventually reset and bring the valuation closer to peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.